SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001837607-24-000008
Filing Date
2024-03-28
Accepted
2024-03-28 16:06:28
Documents
17
Period of Report
2024-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20240324x8k.htm   iXBRL 8-K 52486
2 EX-4.1 aeon-20240324xex4d1.htm EX-4.1 179292
3 GRAPHIC aeon-20240324xex4d1002.jpg GRAPHIC 935
  Complete submission text file 0001837607-24-000008.txt   456351

Data Files

Seq Description Document Type Size
4 EX-101.SCH aeon-20240324.xsd EX-101.SCH 4361
5 EX-101.DEF aeon-20240324_def.xml EX-101.DEF 14402
6 EX-101.LAB aeon-20240324_lab.xml EX-101.LAB 16785
7 EX-101.PRE aeon-20240324_pre.xml EX-101.PRE 14790
20 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240324x8k_htm.xml XML 7177
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 24798854
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)